Volume 32 Issue 3, March 2014

Editorial

Is this really the RNAissance?

Renewed investor interest in RNA interference (RNAi) is enabling pioneering companies to forge ahead in the clinic. Does this signify a renaissance in RNAi therapy?

Editorial 10 Mar 2014

Advertisement

Top of page ⤴

News

Markets, venture investors and big pharma interest in RNAi soars

Aaron Bouchie
News 10 Mar 2014
First integrin inhibitor since Tysabri nears approval for IBD

Cormac Sheridan
News 10 Mar 2014
GSK picks six cancer research centers

Suzanne Elvidge
News 10 Mar 2014
Intercept price quadruples in a day

Brian Orelli
News 10 Mar 2014
Amgen and Regeneron push for a genetic renaissance in drug discovery

Michael Eisenstein
News 10 Mar 2014
BMS sells diabetes business

Asher Mullard
News 10 Mar 2014
First recombinant Factor XIII approved

Emma Dorey
News 10 Mar 2014
Around the world in a month

News 10 Mar 2014
Myriad diversifies, fights rearguard action on patents

Malorye Allison
News 10 Mar 2014
Microbes unite Novozymes and Monsanto

Jeffrey L Fox
News 10 Mar 2014
Roche bets on alpha-synuclein for Parkinson's

Gunjan Sinha
News 10 Mar 2014

Top of page ⤴

Correction

Corrections

Correction 10 Mar 2014

Top of page ⤴

Bioentrepreneur

Acquiring orphans

Will your orphan drug startup draw acquisition interest?

Rogier Rooswinkel
Geert-Jan Mulder
Sander van Deventer
Bioentrepreneur 10 Mar 2014
Startups on the menu: Circuit Therapeutics

Bioentrepreneur 10 Mar 2014

Top of page ⤴

Correspondence

Interactive visualization and analysis of large-scale sequencing datasets using ZENBU

Jessica Severin
Marina Lizio
Alistair R R Forrest

Collection:

The FANTOM5 Project
Correspondence 10 Mar 2014
OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data

Hannes L Röst
George Rosenberger
Ruedi Aebersold
Correspondence 10 Mar 2014
ProteomeXchange provides globally coordinated proteomics data submission and dissemination

Juan A Vizcaíno
Eric W Deutsch
Henning Hermjakob
Correspondence 10 Mar 2014

Top of page ⤴

Commentary

From the analyst's couch: The outlook for biotech exits

The spectacular performance of biopharma companies in the public markets last year has carried over into optimism for early 2014. Will the boom continue?

Annette Grimaldi
Commentary 10 Mar 2014

Top of page ⤴

Feature

Nature Biotechnology's academic spinouts of 2013

Ventures focusing on gene therapy, adoptive T-cell therapy, protein homeostasis and the microbiome are among those selected by the editors in 2013's crop of startups.

Aaron Bouchie
Malorye Allison
Laura DeFrancesco
Feature 10 Mar 2014

Top of page ⤴

Patents

Recent patent applications in chimeric antigen receptors

Patents 10 Mar 2014

Top of page ⤴

News & Views

Casting light on pain

Optogenetic methods to control nociceptors open up a wealth of potential applications in pain research and therapy.

Liam E Browne
Clifford J Woolf
News & Views 10 Mar 2014
E. coli network upgrade

Combining yeast two-hybrid data with mass-spectrometry and structural data provides a detailed view of the E. coli interactome.

Ulrich Stelzl
News & Views 10 Mar 2014
You are what you eat

Eating foods rich in plant fiber promotes health by changing the composition and metabolic products of gut bacteria.

Harald Brüssow
Scott J Parkinson
News & Views 10 Mar 2014
Research Highlights

News & Views 10 Mar 2014

Top of page ⤴

Analysis

Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls

Zook et al. describe methods for integrating genome variants from five sequencing technologies to characterize the first benchmark sample that can be used to understand accuracy of human whole-genome and targeted sequencing.

Justin M Zook
Brad Chapman
Marc Salit
Analysis 16 Feb 2014

Top of page ⤴

Perspective

Mesenchymal stem cells: immune evasive, not immune privileged

James A Ankrum
Joon Faii Ong
Jeffrey M Karp
Perspective 23 Feb 2014

Top of page ⤴

Article

Whole-genome haplotyping using long reads and statistical methods

Haplotyping of human genomes is improved by augmenting experimental dilution-based haplotyping with statistical analyses, a strategy known until now only as 'Moleculo.'

Volodymyr Kuleshov
Dan Xie
Michael Snyder
Article 23 Feb 2014
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library

CRISPR-Cas9 genome editing technology is used for genome-wide genetic screens in mouse embryonic stem cells.

Hiroko Koike-Yusa
Yilong Li
Kosuke Yusa
Article 23 Dec 2013

Top of page ⤴

Letter

Virally mediated optogenetic excitation and inhibition of pain in freely moving nontransgenic mice

Viral delivery of opsins to peripheral nociceptors allows optogenetic stimulation and inhibition of pain in non-transgenic freely moving mice.

Shrivats Mohan Iyer
Kate L Montgomery
Scott L Delp
Letter 16 Feb 2014
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

Guide RNAs with shorter regions of complementarity to target sites reduce off-target effects.

Yanfang Fu
Jeffry D Sander
J Keith Joung
Letter 26 Jan 2014

Top of page ⤴

Resource

The binary protein-protein interaction landscape of Escherichia coli

Yeast-two hybrid screening of E. coli proteins and integration with protein structure and genetic interaction data provides an extensive interactome resource.

Seesandra V Rajagopala
Patricia Sikorski
Peter Uetz
Resource 23 Feb 2014

Top of page ⤴

Corrigendum

Correction: Corrigendum: Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories

Peter A C 't Hoen
Marc R Friedländer
Tuuli Lappalainen
Corrigendum 10 Mar 2014

Top of page ⤴

Erratum

Erratum: A single-molecule long-read survey of the human transcriptome

Donald Sharon
Hagen Tilgner
Michael Snyder
Erratum 10 Mar 2014
Erratum: Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure

Suraj J Patel
Jack M Milwid
Martin L Yarmush
Erratum 10 Mar 2014

Top of page ⤴

Corrigendum

Correction: Corrigendum: In search of dry powder

Jonathan Behr
Phil Murray
Corrigendum 10 Mar 2014

Top of page ⤴

Careers and Recruitment

Profiling the reform-era life sciences executive

Healthcare's reform era is here, requiring executives in the life sciences industry to think differently about their skill sets and capabilities.

John McLean
Careers and Recruitment 10 Mar 2014
People

Careers and Recruitment 10 Mar 2014

Top of page ⤴

Volume 32 Issue 3, March 2014

Editorial

News

Correction

Bioentrepreneur

Correspondence

Commentary

Feature

Patents

News & Views

Analysis

Perspective

Article

Letter

Resource

Corrigendum

Erratum

Corrigendum

Careers and Recruitment

Search

Quick links